Over the last decade immunotherapy has become an integral part of the oncogenic treatment arsenal. Meanwhile, the field of immune-oncology continues to evolve, which was amply illustrated by the large number of studies evaluating innovative immunotherapies presented at ASCO 2021.

(BELG J MED ONCOL 2021;15(5):218-23)